First USP OK for rHAs a "significant advantage", says Novozymes

from Outsourcing-Pharma Podcast · host William Reed Ltd

Two recombinant human albumins made by Novozymes' biopharma division have become the first to comply with the USP-NF's recently revised excipient monograph.

Episode metadata supplied by the publisher feed · Published May 3, 2009

Embed this episode

Attribution link and audio player

NOW PLAYING

First USP OK for rHAs a "significant advantage", says Novozymes

0:00 5:19

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Outsourcing-Pharma Podcast?

This episode is 5 minutes long.

When was this Outsourcing-Pharma Podcast episode published?

This episode was published on May 3, 2009.

Can I download this Outsourcing-Pharma Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!